LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) is set to participate in the 26th Annual Barclays Global Healthcare Conference. The event, scheduled for March 14, 2024, will feature a fireside chat with Savara’s management team.
The discussion, which will be webcast live at 5 AM Pacific Time and 8 AM Eastern Time, offers an opportunity for industry stakeholders to gain insights into Savara’s latest developments and strategic direction. The webcast will be available on Savara’s website and will be archived for 90 days.
Savara is renowned for its commitment to addressing rare respiratory conditions, particularly through its lead program, molgramostim nebulizer solution. This inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) is presently in Phase 3 development concerning autoimmune pulmonary alveolar proteinosis (aPAP). The drug is delivered via an investigational eFlow® Nebulizer System, developed by PARI Pharma GmbH.
The management team at Savara brings a wealth of experience in rare respiratory diseases, pulmonary medicine, and product commercialization. The upcoming fireside chat at the Barclays conference will provide them with an opportunity to shed light on their strategies for tackling unmet needs in this critical healthcare sector.
The fireside chat represents a significant moment for Savara, as it provides an opportunity to share its progress and future plans with a broader audience. The company aims to highlight its ongoing commitment to improving treatment options for patients suffering from rare respiratory diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.